Ocugen Inc. (NASDAQ: OCGN) announced 12-month results from its Phase 2 ArMaDa clinical trial testing OCU410 gene therapy for geographic ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE